Skip to main content
NVCT logo

NVCT · Nuvectis Pharma, Inc.

$19.08 +1.05 (+5.82%) At close · Jul 21
Market Cap
$511.68M
Shares
26.53M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Net Income
-$26.44M -39.2%
FY2025 Net Income FY2022–FY2025
Diluted EPS
-$1.32 -18.9%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$16.01M -30.7%
FY2025 Operating Cash Flow FY2022–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022
$18.58M $18.15M $12.92M $15.38M $13.23M
$9.69M $9.42M $6.93M $7.52M $6.01M
-$28.27M -$27.57M -$19.85M -$22.9M -$19.23M
-$27.16M -$26.44M -$19M -$22.26M -$19.09M
-$29.59M -$28.87M -$19M -$22.26M -$19.09M
USD/shares -$1.32 -$1.11 -$1.43 -$1.51
USD/shares -$1.32 -$1.11 -$1.43 -$1.51
shares 21.81M 17.11M 15.56M 12.66M
shares 21.81M 17.11M 15.56M 12.66M
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.68×
EV/EBIT
Biotechnology median 26.56×
P/E (TTM)
Biotechnology median 7.21×
Key facts CIK 1875558 CUSIP 67080T108 13F (30d) 6 filings 6 filers Visit website Investor relations